A Bioequivalence Study of Capecitabine Tablets

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
1. purpose: To conduct the relative bioavalability study of Capecitabine tablets 500 mg (Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd.) versus XELODA® 500 mg tablets (Manufactured by Roche Pharma AG) 2. Experimental Design: Two-period crossover design 3. Test drug: Capecitabine tablets Reference drug: XELODA 4. Sample size:24
Epistemonikos ID: 902ae49e62b557eeeda625b51b2de31f04e000a7
First added on: May 11, 2024